ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA